Acadia Pharmaceuticals | ACAD - Operating Profit


Acadia Pharmaceuticals reported $71.72M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
J&J USD 6.47B 1B Sep/2026
Moderna USD -815M 573M Jun/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Pfizer USD 662M 5M Sep/2026
Prothena USD -18.69M 44.48M Jun/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026